VipRoids
Active member
Which compound sold in this section actually went through approval, and why does nobody lead with that.
Tesamorelin is a GHRH analog that reached prescription status for a narrow indication, visceral fat accumulation in a specific patient population. It is the rare case where the molecule sitting in a gray market vial has an approved counterpart with a real label, real contraindications and real monitoring requirements.
That is precisely why the market does not talk about it. An approved version arrives with a package insert that states who should not take it, what to monitor, and what the trial data actually supported. A research vial arrives with a purity sheet. Same molecule, radically different quantity of information, and the marketing consistently prefers the version with less.
If the evidence was strong enough to satisfy a regulator for one indication, why is the conversation here built entirely around the vial and never around the label.
Tesamorelin is a GHRH analog that reached prescription status for a narrow indication, visceral fat accumulation in a specific patient population. It is the rare case where the molecule sitting in a gray market vial has an approved counterpart with a real label, real contraindications and real monitoring requirements.
That is precisely why the market does not talk about it. An approved version arrives with a package insert that states who should not take it, what to monitor, and what the trial data actually supported. A research vial arrives with a purity sheet. Same molecule, radically different quantity of information, and the marketing consistently prefers the version with less.
If the evidence was strong enough to satisfy a regulator for one indication, why is the conversation here built entirely around the vial and never around the label.